SCHEMBL23878619

SCHEMBL23878619

CCOC(=O)CC(=O)c1nc(Cl)cn1NC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.35
MAPT P10636 4/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 3/20 0.33
GAA P10253 3/20 0.33
PKM P14618 2/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MGAM O43451 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
ABCB1 P08183 1/20 0.32
TP53 P04637 1/20 0.32
STK17B O94768 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15507057 0.87 ALDH1A1 (0.35) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL22858026 0.86 ABCB1 (0.38) ALDH1A1MAPTCYP1A2KDM4EKMT2A
SCHEMBL22858029 0.81 ALDH1A1 (0.32) ALDH1A1MAPTL3MBTL1KDM4EGAA
SCHEMBL15507033 0.73 ABCB1 (0.38) ALDH1A1MAPTCYP1A2HTTKDM4E
SCHEMBL24075090 0.73 ALDH1A1 (0.35) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL32679879 0.72 NPC1 (0.33) L3MBTL1GAAMEN1KMT2ASMN1; SMN2
SCHEMBL30992460 0.71 ABCB1 (0.41) MAPTCYP1A2CYP2C9CYP2C19HTT
SCHEMBL30992642 0.71 ABCB1 (0.38) ALDH1A1CYP1A2KDM4EGAAHPGD
SCHEMBL15507244 0.68 ALDH1A1 (0.31) ALDH1A1MAPTL3MBTL1KDM4EABCB1
SCHEMBL15507032 0.68 ABCB1 (0.36) ALDH1A1MAPTKDM4EHPGDABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034141-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-30 US disclosed
US-12152027-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-11-26 US disclosed
CN-118420620-A Heterocyclic compounds 武田药品工业株式会社 2024-08-02 CN disclosed
CN-113038948-B Heterocyclic compounds 武田药品工业株式会社 2024-07-12 CN disclosed
US-11897879-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-02-13 US disclosed
US-20220089595-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2022-03-24 US disclosed
US-20220048916-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-02-17 US disclosed
US-11230545-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-25 US disclosed
US-20210332045-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-10-28 US disclosed
EP-3888652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2021-10-06 EP disclosed
CN-113038948-A Heterocyclic compounds 武田药品工业株式会社 2021-06-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089595-A1 HETEROCYCLIC COMPOUND MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885
US-20250034141-A1 HETEROCYCLIC COMPOUND MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885
US-11230545-B2 Heterocyclic compound MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885
US-20210332045-A1 HETEROCYCLIC COMPOUND MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885
US-12152027-B2 Heterocyclic compound MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885
US-20220048916-A1 HETEROCYCLIC COMPOUND MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885
US-11897879-B2 Heterocyclic compound MALT1, SQSTM1, PPM1D ALDH1A1 1199/4885MAPT 1683/4885CYP1A2 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.